Search

Your search keyword '"O, Daldoul"' showing total 9 results
Start Over Author "O, Daldoul"
9 results on '"O, Daldoul"'

2. [The use of neuron specific enolase in the prognosis and followup of neuroblastoma in children. Results of a retrospective series of 21 patients]

Author

M, Abdennebi, H, Boussen, L, Harzallah, O, Daldoul, A, Ghanem, A, Gamoudi, F, Ben Slimene, K, Rahal, A, el May, F, Ben Ayed, and F, Guemira

Subjects
Male, Infant, Prognosis, Sensitivity and Specificity, Immunoenzyme Techniques, Neuroblastoma, Child, Preschool, Phosphopyruvate Hydratase, Biomarkers, Tumor, Humans, Female, Child, Follow-Up Studies, Neoplasm Staging, Retrospective Studies
Abstract

To report the results of seric neuron specific enolase in pediatric neuroblastoma.Our retrospective study concerns 21 children treated in our institution from 1992 to 1998 for neuroblastoma. Seric NSE was determined by immunoenzymology technique at different stages of the disease and the treatment.Mean value for the 39 dosages of the whole patients was 127.9 ng/ml with a sensitivity of 56%, five patients has presented normal values. Mean value for the 18 patients in stage IV was 132.38 ng/ml. We also observed in 3 patients, an evolution of the seric NSE parallel to this of the disease under chemotherapy.NSE represents a moderate sensitive and specific tumor marker for pediatric neuroblastoma. However, it represents a good value in prognosis and follow-up after chemotherapy.

Published
2000

3. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases]

Author

H, Boussen, F, Mezzi, A, Gamoudi, O, Daldoul, H, Ben Hamida, A, Mezlini, S, Khalfallah, S, Karray, K, Ben Romdhane, M, Ben Ghachem, M, Ben Abdallah, M, Douik, A, Saadi, F, Ben Ayed, and H, Ben Hassine

Subjects
Adult, Male, Analysis of Variance, Osteosarcoma, Adolescent, L-Lactate Dehydrogenase, Leucovorin, Bone Neoplasms, Alkaline Phosphatase, Magnetic Resonance Imaging, Survival Analysis, Bleomycin, Methotrexate, Chemotherapy, Adjuvant, Doxorubicin, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Dactinomycin, Humans, Female, Prospective Studies, Child, Tomography, X-Ray Computed, Cyclophosphamide
Abstract

We report the results of a prospective Tunisian study using primary chemotherapy followed by conservative surgery in primitive limb osteosarcoma. From January 1988 to January 1998, 56 patients affected by limb osteosarcoma entered in a prospective study of neoadjuvant chemotherapy with the T10 protocol before surgery with a conservative intent. Initial work-up include: clinical exam with tumor measurements, chest and limb X-rays, limb CT-scan or MRI, chest CT-scan, bone scintigraphy and hematological and renal biological exams. Patients receive pre- and post-operative chemotherapy according to the T10 modified protocol. Fifty-six patients (33 M/23 F) with a mean age of 19 years (8 to 28) are included. Mean clinical and radiological tumor size is around 14 cm. Main histologic type is classic osteosarcoma (50% of cases) and 10 patients (9%) presented with initial metastasis; 42 patients on 56 receive the whole pre-operative protocol. Treatment is well tolerated excluding 18 episodes of mucositis, 29 of leucopenia (grade 3), 7 of thrombopenia (grade 3), 4 of cutaneous toxicity, 2 of pulmonary toxicity and 3 of nausea-vomiting. We observe 36% of good histological responders and 64% of bad responders to primary chemotherapy, 27 patients on 49 operated (53%) have a conservative surgery and 18 (47%) a radical surgery. With a median follow-up of 51 months (8 to 128), 29 patients remain alive free of disease (15/17 GR and 14/30 BR), 2 are alive with disease, 2 died by toxicity, 14 died by progressive disease and 9 are lost to follow-up with evolutive disease. Five year disease-free survival is 55% for the 46 non metastatic patients. In univariate analysis, seric alkaline phosphatase level (p = 0.0014) and histological response to chemotherapy (p = 0.0218) are significant factors for prognosis.

Published
2000

4. P147 Alimentation spontanée d’un groupe de patients atteints d’un cancer broncho-pulmonaire primitif

Author

C. Hmida, N. Trabelsi, A. Loukil, S. Dakhli, N. Dakhli, A. Trimeche, O. Daldoul, F. Ben Mami, M. Boughanmi, N. Fendri, Ahmed Achour, and I. Ben Ammar

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine, General Medicine
Abstract

Introduction Dans le cancer bronchique, differents facteurs participent a l'alteration de l'etat nutritionnel des patients. La diminution des apports alimentaires reste la cause la plus frequente et la plus importante de deterioration nutritionnelle. Objectifs Analyser l'alimentation spontanee d'un groupe de patients atteints d'un cancer broncho-pulmonaire primitif et ce avant tout traitement a base de chimiotherapie. Evaluer l'etat nutritionnel initial des patients atteints d'un cancer broncho-pulmonaire primitif. Patients et Methodes Etude prospective ayant concerne 20 patients porteurs d'un cancer du poumon suivis a l'Institut Salah Azaiez. Nos patients ont repondu a un questionnaire comportant des renseignements generaux et medicaux (le stade du cancer, la presence de comorbidite…) et a une enquete alimentaire realisee selon la technique de l'histoire alimentaire. Resultats Notre serie est constituee de 20 patients dont 19 hommes. Ils ont un âge moyen de 61 ± 10 ans. Le poids moyen est de 59,5 ± 11,05 kg. L'IMC moyen est de 21,5 ± 3 kg/m 2 . 20 % des patients presentent une maigreur. La moitie des patients sont denutris et cette denutrition est severe chez 10 % de la population. 20 % des patients ont un regime hypocalorique, 40 % ont un regime hypoglucidique, 35 % ont un regime hypolipidique et 50 % ont un regime hypoprotidique. Cet apport protidique est inferieur a 1,25 g/kg/j chez 75 % des patients. L'apport en fibres est insuffisant chez la moitie des patients. L'analyse de l'apport en sels mineraux, oligoelements et vitamines retrouve un deficit concernant surtout le potassium, le calcium, le phosphore, le zinc, les vitamines E et B1. Conclusion La denutrition est importante chez ce groupe de patients cancereux. Une prise en charge nutritionnelle rigoureuse pourrait ameliorer la qualite et l'esperance de vie de ces patients fragilises et reduire l'incidence d'eventuelles complications liees aux traitements.

Published
2010
Full Text
View/download PDF

6. [Trastuzumab (herceptin) for the medical treatment of breast cancer].

Author

Bayoudh L, Afrit M, Daldoul O, Zarrad M, and Boussen H

Subjects
Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Female, Humans, Receptor, ErbB-2 antagonists & inhibitors, Trastuzumab, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy
Abstract

Background: Trastuzumab is humanized monoclonal antibody targeting her 2 neu receptor, overexpressed in 20% of breast cancers and part of the complex of Epidermal Growth Factor Receptor., Aim: To review new advances in the knowledge of the practical use of "trastuzumab (Herceptin ®)" in breast cancer., Methods: Review of literature using medical data bases (Medline, Science direct) with the following key words: breast cancer, targeted therapy, HER2 neu, transtuzumab/herceptine, Results: Trastuzumab represent an important advance in breast cancer treatment with an improvement of median survival in metastatic setting and overall and disease-free survival in adjuvant setting in association with chemotherapy. Herceptin remain well tolerated with a low and rare risk of cardiac failure., Conclusion: Trastuzumab is a new therapeutic tool very interesting to ameliorate prognosis of breast cancer.

Published
2012

7. [Update on medical therapies of nasopharyngeal carcinomas].

Author

Boussen H, Bouaouina N, Daldoul O, Benna F, Gritli S, and Ladgham A

Subjects
Adolescent, Age of Onset, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma pathology, Child, Child, Preschool, Combined Modality Therapy methods, Disease-Free Survival, Dose Fractionation, Radiation, Humans, Infant, Infant, Newborn, Lymphatic Metastasis, Nasopharyngeal Neoplasms pathology, Neoplasm Staging, Treatment Outcome, Tumor Burden, Carcinoma drug therapy, Carcinoma radiotherapy, Nasopharyngeal Neoplasms drug therapy, Nasopharyngeal Neoplasms radiotherapy
Abstract

Nasopharyngeal carcinomas (NPC) are predominantly of undifferentiated type (UCNT or undifferentiated carcinoma of nasopharyngeal type), rare (<1/100,000) and sporadic in occidental countries, but endemic in the Mediterranean area of intermediate incidence (2 to 10/100,000) and highly frequent (>10/100,000) in South East Asia. NPC staging is based on TNM UICC 2002 that has a prognostic and therapeutic orientation impact. Irradiation of the primitive tumor and its extensions remains the standard loco-regional treatment. The recent introduction of primary and concomitant chemotherapy leads to an improvement in terms of overall and disease-free survival, specially for for high-risk-patients (T3-4 and N2-3 disease). Prognosis remain linked to T, N, histologic type and quality of response to chemotherapy and radiotherapy.

Published
2010
Full Text
View/download PDF

8. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases].

Author

Boussen H, Mezzi F, Gamoudi A, Daldoul O, Ben Hamida H, Mezlini A, Khalfallah S, Karray S, Ben Romdhane K, Ben Ghachem M, Ben Abdallah M, Douik M, Saadi A, Ben Ayed F, and Ben Hassine H

Subjects
Adolescent, Adult, Alkaline Phosphatase blood, Analysis of Variance, Biomarkers, Tumor blood, Bleomycin administration & dosage, Bone Neoplasms pathology, Bone Neoplasms surgery, Chemotherapy, Adjuvant, Child, Cyclophosphamide administration & dosage, Dactinomycin administration & dosage, Doxorubicin administration & dosage, Female, Humans, L-Lactate Dehydrogenase blood, Leucovorin administration & dosage, Magnetic Resonance Imaging, Male, Methotrexate administration & dosage, Osteosarcoma pathology, Osteosarcoma surgery, Prospective Studies, Survival Analysis, Tomography, X-Ray Computed, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Osteosarcoma drug therapy
Abstract

We report the results of a prospective Tunisian study using primary chemotherapy followed by conservative surgery in primitive limb osteosarcoma. From January 1988 to January 1998, 56 patients affected by limb osteosarcoma entered in a prospective study of neoadjuvant chemotherapy with the T10 protocol before surgery with a conservative intent. Initial work-up include: clinical exam with tumor measurements, chest and limb X-rays, limb CT-scan or MRI, chest CT-scan, bone scintigraphy and hematological and renal biological exams. Patients receive pre- and post-operative chemotherapy according to the T10 modified protocol. Fifty-six patients (33 M/23 F) with a mean age of 19 years (8 to 28) are included. Mean clinical and radiological tumor size is around 14 cm. Main histologic type is classic osteosarcoma (50% of cases) and 10 patients (9%) presented with initial metastasis; 42 patients on 56 receive the whole pre-operative protocol. Treatment is well tolerated excluding 18 episodes of mucositis, 29 of leucopenia (< grade 3), 7 of thrombopenia (< grade 3), 4 of cutaneous toxicity, 2 of pulmonary toxicity and 3 of nausea-vomiting. We observe 36% of good histological responders and 64% of bad responders to primary chemotherapy, 27 patients on 49 operated (53%) have a conservative surgery and 18 (47%) a radical surgery. With a median follow-up of 51 months (8 to 128), 29 patients remain alive free of disease (15/17 GR and 14/30 BR), 2 are alive with disease, 2 died by toxicity, 14 died by progressive disease and 9 are lost to follow-up with evolutive disease. Five year disease-free survival is 55% for the 46 non metastatic patients. In univariate analysis, seric alkaline phosphatase level (p = 0.0014) and histological response to chemotherapy (p = 0.0218) are significant factors for prognosis.

Published
2000

9. [The use of neuron specific enolase in the prognosis and followup of neuroblastoma in children. Results of a retrospective series of 21 patients].

Author

Abdennebi M, Boussen H, Harzallah L, Daldoul O, Ghanem A, Gamoudi A, Ben Slimene F, Rahal K, el May A, Ben Ayed F, and Guemira F

Subjects
Child, Child, Preschool, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Infant, Male, Neoplasm Staging, Neuroblastoma blood, Neuroblastoma pathology, Neuroblastoma secondary, Prognosis, Retrospective Studies, Sensitivity and Specificity, Biomarkers, Tumor blood, Neuroblastoma drug therapy, Phosphopyruvate Hydratase blood
Abstract

Objective: To report the results of seric neuron specific enolase in pediatric neuroblastoma., Patients and Methods: Our retrospective study concerns 21 children treated in our institution from 1992 to 1998 for neuroblastoma. Seric NSE was determined by immunoenzymology technique at different stages of the disease and the treatment., Results: Mean value for the 39 dosages of the whole patients was 127.9 ng/ml with a sensitivity of 56%, five patients has presented normal values. Mean value for the 18 patients in stage IV was 132.38 ng/ml. We also observed in 3 patients, an evolution of the seric NSE parallel to this of the disease under chemotherapy., Conclusion: NSE represents a moderate sensitive and specific tumor marker for pediatric neuroblastoma. However, it represents a good value in prognosis and follow-up after chemotherapy.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results